Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Boxer Mark Weinman, who returned from a nearly 21-year layoff to win a professional bout at age 50, has died. He was 62. Weinman, from the borough of Queens in New York City, died Feb. 8 in Mesa, ...

Canaccord Genuity Capital Markets has downgraded Pliant Therapeutics (NASDAQ:PLRX) to hold from buy following news that the company has paused a clinical trial for its drug bexotegrast in the ...

Columnist Sam Kirton has spent years finding calm through a popular British phrase, which has allowed him to carry on through medical crises.

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 ...

FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...